Allergan

Morgan Stanley continues to recommend Allergan Inc. (NYSE: AGN) with a PT of $85. “Many investors wonder about what is in Allergan Inc.'s pipeline, so we conducted a deep dive analysis on clinical trial websites to try to uncover public information to facilitate analysis,” Morgan Stanley writes...

In a report published by Citi, Allergan (NYSE: AGN) Presented Positive Results for its First Botox Phase III Trial in Neurogenic Overactive Bladder (OAB) at the European Association of Urology (EAU) meeting in Vienna. Citi said that the positive data was expected since AGN filed its supplementary...

Morgan Stanley has published a research report on Allergan Inc. (NYSE: AGN) in anticipation of the company's Botox bladder expert call scheduled for March 22nd. In the report, Morgan Stanley writes "We are hosting Dr. Michael Chancellor at 9AM on Tuesday, March 22, to discuss the first Phase III...

Jefferies is out with its report today on Allergan (NYSE: AGN), maintaining Hold and a $74 PT. In its note to clients, Jefferies writes, "AGN has in-licensed Levadex, a Phase III therapy for acute migraine. This builds on AGN's CNS/neurology franchise, especially now that Botox for chronic...

Piper Jaffray remains bullish on Allergan, Inc.'s (NYSE: AGN) growth prospects, both near- and long-term, and expect that 4Q10 is likely to be another solid quarter (Piper Jaffray is at $0.89, in line with the Street), driven by continued year-over-year growth for key medical aesthetics products...

Citigroup has published a research report on Allergan Inc. (NYSE: AGN) after the FDA voted in facor or broading the lap-band label to include lower BMI patients. In the report, Citigroup writes "We expect the Lap-Band label to be expanded to include patients with ≥30 kg/m2 Body Mass Index (BMI) +...

Allergan Inc. (NYSE: AGN) has an overweight rating thanks in part to the use of Botox for migraines. Dr. John Rothrock, a leader in the treatment of migraines, spoke to Piper Jaffray about the usage of Botox for patients with chronic migraines. Dr. Rothrock notices a benefit when Botox is used for...

After the close on Friday, 10/15/10, Allergan, Inc. (NYSE: AGN) announced that the FDA approved Botox for chronic migraine (CM), Wells Fargo reports, noting that the approval came a few weeks sooner than we expected. “We view this news very positively because we believe the CM indication will...

RBC Capital Markets has reiterated its ratings on the following companies: Ametek (NYSE: AME) Outperform, price target raised from $50 to $55 Middleby (NASDAQ: MIDD) Sector Perform, price target raised from $64 to $70 Oil States (NYSE: OIS) Outperform, price target raised from $56 to $58 Genuine...

Piper Jaffray reports this morning that it is confident that Allergan, Inc. (NYSE: AGN) will soon gain approval to use Botox to treat migraine headaches. “With a near-term approval in migraine looking likely, and with another solid quarter likely (we are at an EPS of $0.80, versus the Street...